Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
185.51 x 3 185.95 x 7
Post-market by (Cboe BZX)
186.06 +5.69 (+3.15%) 04/25/25 [NYSE]
185.51 x 3 185.95 x 7
Post-market 185.94 -0.12 (-0.06%) 19:54 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
179.99
Day High
188.70
Open 187.12
Previous Close 180.37 180.37
Volume 10,482,000 10,482,000
Avg Vol 9,826,370 9,826,370
Stochastic %K 53.79% 53.79%
Weighted Alpha +11.23 +11.23
5-Day Change +13.07 (+7.56%) +13.07 (+7.56%)
52-Week Range 153.58 - 218.66 153.58 - 218.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 330,728,128
  • Shares Outstanding, K 1,768,978
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,130 M
  • EBITDA $ 17,516 M
  • 60-Month Beta 0.55
  • Price/Sales 5.84
  • Price/Cash Flow 12.46
  • Price/Book 97.74

Options Overview Details

View History
  • Implied Volatility 26.22% ( -8.86%)
  • Historical Volatility 38.12%
  • IV Percentile 82%
  • IV Rank 28.24%
  • IV High 51.27% on 04/08/25
  • IV Low 16.36% on 05/10/24
  • Put/Call Vol Ratio 0.26
  • Today's Volume 58,588
  • Volume Avg (30-Day) 33,618
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 411,124
  • Open Int (30-Day) 396,152

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 3.09
  • Number of Estimates 7
  • High Estimate 3.32
  • Low Estimate 2.78
  • Prior Year 2.65
  • Growth Rate Est. (year over year) +16.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.39 +13.18%
on 04/09/25
Period Open: 201.34
212.15 -12.30%
on 04/01/25
-15.28 (-7.59%)
since 03/25/25
3-Month
164.39 +13.18%
on 04/09/25
Period Open: 170.30
218.66 -14.91%
on 03/10/25
+15.76 (+9.25%)
since 01/24/25
52-Week
153.58 +21.15%
on 05/30/24
Period Open: 167.29
218.66 -14.91%
on 03/10/25
+18.77 (+11.22%)
since 04/25/24

Most Recent Stories

More News
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off

It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying...

ZTS : 153.47 (+0.77%)
ABBV : 186.06 (+3.15%)
AMGN : 280.84 (+0.36%)
BMY : 47.90 (-1.62%)
Why AbbVie Stock Topped the Market Today

A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (NYSE: ABBV) stock an investor darling on Friday. The pharmaceutical company's performance...

NFLX : 1,101.53 (+0.42%)
NVDA : 111.01 (+4.30%)
ABBV : 186.06 (+3.15%)
Stocks Finish Higher as Megacap Tech Stocks Rally

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.74%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.14%. June E-mini S&P futures...

GOOGL : 161.96 (+1.68%)
SKX : 47.79 (-5.35%)
AAPL : 209.28 (+0.44%)
DLR : 159.88 (+3.99%)
$IUXX : 19,432.56 (+1.14%)
ZNM25 : 111-165s (+0.27%)
MSFT : 391.85 (+1.17%)
TSLA : 284.95 (+9.80%)
ESM25 : 5,549.75s (+0.70%)
$DOWI : 40,113.50 (+0.05%)
SPY : 550.64 (+0.72%)
DIA : 401.02 (+0.01%)
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View

AbbVie Inc. ABBV reported first-quarter 2025 adjusted earnings per share (EPS) of $2.46, which beat the Zacks Consensus Estimate of $2.39. The reported EPS also exceeded the company’s guidance of $2.34-$2.38...

JNJ : 154.58 (-0.23%)
ABBV : 186.06 (+3.15%)
RHHBY : 39.5200 (-0.58%)
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.

ABT : 128.85 (-0.41%)
ABBV : 186.06 (+3.15%)
AbbVie (NYSE:ABBV) Reports Bullish Q1

AbbVie (NYSE:ABBV) Reports Bullish Q1

ABBV : 186.06 (+3.15%)
AbbVie: Q1 Earnings Snapshot

AbbVie: Q1 Earnings Snapshot

ABBV : 186.06 (+3.15%)
Stock Index Futures Slip Amid U.S.-China Tariff Uncertainty, Alphabet Climbs on Upbeat Results

June S&P 500 E-Mini futures (ESM25) are down -0.32%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.35% this morning as mixed signals on U.S.-China trade relations weighed on investors’ risk...

GOOGL : 161.96 (+1.68%)
NVDA : 111.01 (+4.30%)
FI : 177.53 (+0.36%)
HCA : 327.92 (-3.95%)
SLB : 34.52 (-1.17%)
CL : 93.91 (+1.31%)
TXN : 162.86 (+0.45%)
ABBV : 186.06 (+3.15%)
TMUS : 232.77 (-11.22%)
ESM25 : 5,549.75s (+0.70%)
TSLA : 284.95 (+9.80%)
STER.S.DX : 88.550 (+1.96%)
AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect

AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect

ABBV : 186.06 (+3.15%)
2 High-Yield Dividend Stocks to Buy for Passive Income

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks can do the heavy lifting. The key is focusing on companies with strong yields,...

ABBV : 186.06 (+3.15%)
PFE : 22.92 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 198.55
2nd Resistance Point 193.63
1st Resistance Point 189.84
Last Price 186.06
1st Support Level 181.13
2nd Support Level 176.21
3rd Support Level 172.42

See More

52-Week High 218.66
Fibonacci 61.8% 193.80
Fibonacci 50% 186.12
Last Price 186.06
Fibonacci 38.2% 178.44
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective